Sutherland Rachel, Steele Maureen, Rodgers Craig, Silins Edmund, Gilliver Rosie, Peacock Amy, Barratt Monica, Ezard Nadine, Siefried Krista J, Page Robert, Bruno Raimondo, Read Phillip
National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW, 2052, Australia.
NSW Ministry of Health, Sydney, Australia.
Harm Reduct J. 2025 May 13;22(1):75. doi: 10.1186/s12954-025-01205-z.
This paper examines: (i) the acceptability of, and behavioural outcomes associated with, take-home fentanyl test strips (FTS), and (ii) support for, and preferences regarding, drug checking services among people who use heroin.
Data were obtained from 78 people who had used heroin in the past 6 months, recruited from treatment and harm reduction services in Sydney, Australia in 2020-21. Participants were provided with 10 BTNX Rapid Response™ single-use immunoassay FTS and surveyed 4 weeks later.
Among those who completed the follow-up survey (n = 72), 81% (n = 58) had used at least one FTS by the time of follow-up (median 6 strips). Participants reported high confidence in their ability to use FTS at both baseline (immediately post training) and follow-up. Of those who self-reported a positive FTS result (n = 25), 48% (n = 12) reported using less than they otherwise would have or starting with a smaller amount, and 60% (n = 15) shared this information with peers and/or health professionals. Of those who used FTS and responded, 95% (n = 54/57) reported that they would continue using FTS if they were free to access, and 97% (n = 56/58) would recommend them to their peers. Among those who completed the follow-up survey, the majority (93%; n = 67) reported that they would like to be able to access a drug checking service, preferably via a supervised injecting facility or Needle and Syringe Program.
Acceptability of FTS and support for drug checking were high among our sample. Multi-instrument approaches to drug checking may form one component of an effective response to the emerging threat of illicitly manufactured synthetic opioids.
本文探讨了:(i)带回家的芬太尼检测试纸(FTS)的可接受性及其相关行为结果,以及(ii)海洛因使用者对毒品检测服务的支持和偏好。
数据来自2020 - 2021年在澳大利亚悉尼的治疗和减少伤害服务机构招募的78名在过去6个月内使用过海洛因的人。为参与者提供了10条BTNX快速反应™一次性免疫分析FTS,并在4周后进行调查。
在完成随访调查的人中(n = 72),81%(n = 58)在随访时至少使用过一条FTS(中位数为6条)。参与者在基线(培训后立即)和随访时均报告对自己使用FTS的能力有高度信心。在自我报告FTS结果为阳性的人中(n = 25),48%(n = 12)报告使用量比原本会使用的少或开始时用量更小,60%(n = 15)与同伴和/或卫生专业人员分享了此信息。在使用FTS并做出回应的人中,95%(n = 54/57)报告如果可以免费获取,他们会继续使用FTS,97%(n = 56/58)会向同伴推荐。在完成随访调查的人中,大多数(93%;n = 67)报告他们希望能够获得毒品检测服务,最好是通过受监管的注射设施或针头和注射器项目。
在我们的样本中,FTS的可接受性和对毒品检测的支持度很高。多仪器毒品检测方法可能构成应对非法制造的合成阿片类药物新出现威胁的有效对策的一个组成部分。